美股异动｜诺和诺德盘前续跌逾2% 实验效果不及礼来

Core Viewpoint - Novo Nordisk (NVO.US) experienced a significant decline of 16.43% in stock price, closing at $39.63, and continued to drop by 2.12% in pre-market trading, reaching $38.79, following the announcement of clinical data for CagriSema which did not meet its primary efficacy endpoint in the REDEFINE 4 trial [1][1][1] Group 1: Clinical Trial Results - The clinical trial for CagriSema demonstrated a weight reduction effect of 23% [1] - However, the results did not achieve the predefined primary goal of being non-inferior to Eli Lilly's Tirzepatide [1] Group 2: Stock Performance - The stock's highest price in the last trading session was $41.09, with a lowest price of $39.34 [1] - The trading volume was 98.664 million shares, with a total market capitalization of $176.948 billion [1] - The stock's price-to-earnings ratio (P/E) is reported at 10.90, and the price-to-book ratio (P/B) is 5.778 [1]